Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization—Clinical Evidence and Challenges
Diagnostic Cytopathology · 2025-11 · 53 (11) · 580-591
DOI: 10.1002/dc.70009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostic Cytopathology, online erschienen am 04.09.2025. Verfasst von Qi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Qianwei Hospital of Jilin Province, Changchun, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Early Detection of Cancer, Neoplasm, Residual. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 202 Literaturangaben.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a major global health burden, ranking among the leading causes of cancer‐related deaths. Despite improvements in screening and treatment, challenges such as late‐stage diagnosis, high recurrence rates, and therapy resistance continue to impede optimal outcomes. Liquid biopsy, a minimally invasive technique that analyzes tumor‐derived components in bodily fluids—including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs)—is emerging as a powerful tool to transform CRC management across the disease continuum. This review provides a comprehensive overview of liquid biopsy's current and emerging applications in CRC. We examine its role in early detection, where sensitive ctDNA‐based assays and epigenetic biomarkers have demonstrated the ability to identify CRC at asymptomatic or early stages, potentially improving screening uptake and compliance. Furthermore, we explore how liquid biopsy enables dynamic monitoring of treatment response and clonal evolution, facilitating the timely identification of resistance mutations and supporting personalized therapy adjustments. Innovations in multi‐omics integration, artificial intelligence, and ultra‐sensitive sequencing technologies are also discussed as pivotal advancements that enhance the clinical utility of liquid biopsy. Despite significant progress, the widespread adoption of liquid biopsy faces several hurdles, including assay standardization, sensitivity for low‐shedding tumors, regulatory approval, and cost‐effectiveness. Continued research, validation in large prospective trials, and harmonization of testing protocols are essential to overcome these challenges. Ultimately, liquid biopsy holds the potential to become a cornerstone of precision oncology in CRC, enabling earlier intervention, more tailored treatment strategies, and improved patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Qianwei Hospital of Jilin Province, Changchun, China.
ORCID-Profile: Nan Liu
Zitieren
APA
Liu, Q., Li, X., Jin, T., Huo, S., Su, S., & Liu, N. (2025). Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization—Clinical Evidence and Challenges. Diagnostic Cytopathology, 53(11), 580-591. https://doi.org/10.1002/dc.70009
Vancouver
Liu Q, Li X, Jin T, Huo S, Su S, Liu N. Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization—Clinical Evidence and Challenges. Diagnostic Cytopathology. 2025;53(11):580-591. doi:10.1002/dc.70009
BibTeX
@article{Liu2025,
author = {Liu, Qi and Li, Xiaoyong and Jin, Tiejun and Huo, Sibo and Su, Shuai and Liu, Nan},
title = {Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization—Clinical Evidence and Challenges},
journal = {Diagnostic Cytopathology},
year = {2025},
volume = {53},
number = {11},
pages = {580--591},
doi = {10.1002/dc.70009}
}
EUVIMED